Johnson & Johnson's 1st-qtr earnings beat while sales miss expectations

18 April 2017

US health care giant Johnson & Johnson (NYSE: JNJ) posted first-quarter 2017 financial results today, posted sales that missed analysts’ predictions while earnings were better than expected, with the announced sending the firm’s share up 1.68% to $123.61 in pre-market trading. However, by mid morning EDT, the stock was down 3.35% at $121.57.

Group sales of $17.8 billion for the first quarter represented an increase of 1.6% compared to the first quarter of 2016. Net earnings drifted 0.8% lower to $4.42 billion from last year's $4.46 billion. Earnings per share, however, grew 1.3% to $1.61 from $1.59 last year. Adjusted net earnings for the latest quarter were $5 billion or $1.83 per share, compared to $4.85 billion or $1.73 per share a year ago.

Analysts expected earnings of $1.76 per share on sales of $18.01 billion for the quarter, according to RTT News. On an operational basis, adjusted diluted earnings per share also increased 7.5%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK